179. Mizuno Y, Yamamoto M, Kuno S, Hasegawa K, Hattori N, Kagimura T, Sarashina A, Rascol O, Schapira AH, Barone P, Hauser RA, Poewe W; Pramipexole ER Study Group. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol. 2012 Jul-Aug;35(4):174-81. doi: 10.1097/WNF.0b013e31825f77b9. PMID: 22801294.
180. Wang Y, Sun SG, Zhu SQ, Liu CF, Liu YM, Di Q, Shang HF, Ren Y, Xiang W, Chen SD. Analysis of pramipexole dose-response relationships in Parkinson's disease. Drug Des Devel Ther. 2016 Dec 23;11:83-89. doi: 10.2147/DDDT.S112723. PMID: 28096656; PMCID: PMC5207331.
181. Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Int J Clin Pract. 2009 Apr;63(4):613-23. doi: 10.1111/j.1742- 1241.2009.02027.x. Epub 2009 Feb 16. PMID: 19222614.
182. Stowe R, Ives N, Clarke CE, Deane K; van Hilten, Wheatley K, Gray R, Handley K, Furmston A. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev. 2010 Jul 7;(7):CD007166. doi: 10.1002/14651858.CD007166.pub2. PMID: 20614454.
183. Yi ZM, Qiu TT, Zhang Y, Liu N, Zhai SD. Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation. Ther Clin Risk Manag. 2018 Apr 16;14:709-719. doi: 10.2147/TCRM.S163190. PMID: 29713179; PMCID: PMC5907888.
184. Li J, Lou Z, Liu X, Sun Y, Chen J. Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta- Analysis. Eur Neurol. 2017;78(3-4):143-153. doi: 10.1159/000479555. Epub 2017 Aug 16. PMID: 28813703.
185. Marsala SZ, Gioulis M, Ceravolo R, Tinazzi M. A systematic review of catechol- 0-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin Neuropharmacol. 2012 Jul-Aug;35(4):185-90. doi: 10.1097/WNF.0b013e31825c034a. PMID: 22805229.
186. Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004554. doi: 10.1002/14651858.CD004554.pub2. PMID: 15495119.
187. Brooks DJ, Sagar H; UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071- 9. doi: 10.1136/jnnp.74.8.1071. PMID: 12876237; PMCID: PMC1738605.
188. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M; Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002 Apr;105(4):245-55. doi: 10.1034/j.1600- 0404.2002.1o174.x. PMID: 11939936.
189. Myllylä VV, Kultalahti ER, Haapaniemi H, Leinonen M; FILOMEN Study Group. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol. 2001 Jan;8(1):53-60. doi: 10.1046/j.1468-1331.2001.00168.x. PMID: 11509081.
190. Armstrong M, Okun M. Diagnostic and Treatment of Parkinson Disease. A Rewiew. JAMA 2020; 323(6):546-560.
191. Левин О.С., Федорова Н.В. Москва, Медпресс, 4-е издание, 2014 г.
192. Balestrino R., Schapira A.H.V. Parkinson Disease .Europien Journal of Neuropogy 2020, 27:27-42.
193. Olanow C.W., Kieburtz K., Odin P. et all. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advances Parkinson’s disease% a randomized, controlled, double-blined, double-dummy study. Lancet Neurol. 2014 Feb;13(2):141-9.
194. Antonini A., Marano P. et all. Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson’s disease: result of the Italian GLORIA patient population. Neurological Sciences, 2020, 41:2929-2937.
195. Antonini A. et all. The Tandem investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel (LCIG) in advanced Parkinson’s disease patients. Journal of Neural Transmission, 2020. 127: 881-891.
196. Honig H., Antonini A. et all. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicentral study of effects on nonmotor symptoms and quality of life. Movement disorders. Vol..24, No 10, 2009, 1468-1474.
197. Zhang XR, Jiang ZY, Zhang ZR, Chen HJ, Wu K, He JC, Xie CL. The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson's Disease: A Systematic Review. Drug Des Devel Ther. 2020 Feb 26;14:845-854. doi: 10.2147/DDDT.S229621. PMID: 32161444; PMCID: PMC7050037.
198. Marsili L, Bologna M, Miyasaki JM, Colosimo C. Parkinson's disease advanced therapies - A systematic review: More unanswered questions than guidance. Parkinsonism Relat Disord. 2021 Feb;83:132-139. doi: 10.1016/j.parkreldis.2020.10.042. Epub 2020 Nov 2. PMID: 33158747.
199. Wang L, Li J, Chen J. Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis. Front Neurol. 2018 Jul 30;9:620. doi: 10.3389/fneur.2018.00620. PMID: 30104997; PMCID: PMC6077236.
200. Wirdefeldt K, Odin P, Nyholm D. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review. CNS Drugs. 2016 May;30(5):381-404. doi: 10.1007/s40263-016-0336-5. PMID: 27138916.
201. Băjenaru O, Ene A, Popescu BO, Szász JA, Sabău M, Mureşan DF, Perju- Dumbrava L, Popescu CD, Constantinescu A, Buraga I, Simu M. The effect of levodopa- carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience. J Neural Transm (Vienna). 2016 Apr;123(4):407-14. doi: 10.1007/s00702-015-1496-z. Epub 2015 Dec 23. PMID: 26699635; PMCID: PMC4805768.